cDC2 are superior to cDC1 for IC for MHC-II presentation. (A) In vivo OT-II proliferation 3 days after adoptive transfer into WT, Δ32, and Δ1+2+3 mice bearing 1956-mOVA tumors. 10⁶ 1956-mOVA cells were subcutaneously injected into mice two days before the OT-II transfer. (B) Frequencies of OT-II proliferation of mice described in A. Data are represented as mean values ± SD of pooled biologically independent samples from two independent experiments (n = 7 for WT and Δ1+2+3; n = 8 Irf8 Δ 32 mice). ns = not significant; *P < 0.05. (C) In vivo OT-II proliferation in WT, Δ32, and Δ1+2+3 mice on day 3 after intravenous immunization with 1 μg of sOVA or OVA-IC. (D) Frequencies of OT-II proliferation from mice described in C. Data represent mean ± SEM of pooled biologically independent samples from two independent experiments. (B) Brown–Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparisons test. (D) Two-way ANOVA with Sidak’s multiple comparisons test, with a single pooled variance. ns = not significant; ****P < 0.0001.